Valsartan decrease expression of endothelin-1 in myocardium of rats with chronic renal failure

Abstract

Abstract: AIM: To observe the therapeutic effect of valsartan on cardiac hypertrophy and expression of endothelin-1(ET-1) in myocardium of rats with chronic renal failure and explore the mechanism.METHODS: 24 Sprague Dawley male rats were selected, and performed five-sixths nephrectomy to produce chronic renal failure model.Two weeks after the surgery, the rats were randomly divided into model group, valsartan group, and a sham group was established serving as control group.Systolic blood pressure, BUN and serum creatinine were measured at ten weeks after operation, then the rats were sacrificed to take the hearts for pathological histological examination.Hybridization in situ was used to examine the transcription of ET-1 mRNA in myocardium.RESULTS: Systolic pressure, heart weight, heart weight index, left ventricular weight mass(LVM) and left ventricular weight mass index (LVMI) in model group increased significantly tenth week after operation.Systolic pressure, heart weight, heart weight index, LVM and LVMI were decreased markedly in rats with five-sixths nephrectomy by valsartan(P<0.01);Hybridization in situ indicated that there was a decreasing expression of ET-1 mRNA in myocardium in valsartan group as compared with model group.CONCLUSION: Valsartan could prevent left ventricular hypertrophy in chronic experiment renal failure rats.The improvement of cardiomyopathy may be through the mechanism of downregulating transcription of ET-1 mRNA in myocardium.

Key words: valsartan, chronic renal failure, left ventricular hypertrophy, endothelin

CLC Number:

R965.1

XU Hai-hong, YANG Li-cai, YANG Yan-lang, ZHANG Dao-you. Valsartan decrease expression of endothelin-1 in myocardium of rats with chronic renal failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(6): 639-643.

References

[1] 王小时, 郑法雷, 刘燕萍. 慢性肾衰的心血管病变[M]//郑法雷, 章友康, 陈香美, 等主编. 肾脏病临床与进展. 北京:人民军医出版社, 2005:278-287.
[2] Shutov AM, Kondrat'eva NI, Kulikova ES, et al. Heart remodeling. In patients with predialysis phase of chronic renal failure[J]. Ter Arkh, 2000, 72(6): 46-49.
[3] London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects[J]. Semin Dial, 2003, 16 (2): 85-94.
[4] Zolk O, Quattek J, Seeland U, et al. Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2) 27 rats[J]. Cardiovasc Res, 2002, 53(2): 363-371.
[5] Ram CV. Possible therapeutic role of endothelin antagonists in cardiovasculardisease[J]. Am J Therapeutics, 2003, l0(6): 396-400.
[6] 秦旭平, 龙光, 徐立朋, 等. 氯沙坦和培哚普利逆转高血压大鼠心血管重构的比较[J]. 中国药理学通报, 2004, 20(10): 1107-1111.
[7] 王迎新, 李远思, 陈燕, 等. 福辛普利与氯沙坦对试验性糖尿病大鼠肾病的防治作用与转化因子β₁的关系[J]. 中国药理学通报, 2005, 21(7): 884-888.
[8] Piuhola J, Szokodi I, Kinnunen P, et al. Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts[J]. Hypertension, 2003, 41(1): 93-98.
[9] Schmieder RE. Endothelial dysfunction:how Can one intervene at the beginning of the cardiovascular continuum[J] ? J Hypertens Suppl, 2006, 24(2): S31-35.
[10] Nakamura K, Yamagishi S, Nakamura Y, et al. Telmisartan inhibitsexpression of a receptor for advanced glycation end products(RAGE) in anglotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension[J]. Microvasc Res, 2005, 70 (3): 137-141.
[11] Baba T, Kanda T, Kobay ashi I. Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice[J]. Life Sci, 2000, 67(5): 587-597.
[12] Naruse M, Tanabe A, Hara Y, et al. Effects of AT1 Receptor Antagonist and Spironolactone on Cardiac Expression of ET-1 mRNA in SHR-SP/Izm[J]. J Cardiovasc Pharmacol, 2004, 44: S1-S3.

[1]	LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.
[2]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[3]	YAN Wenlong, SHU shuhua, LI Juan. Effects of tight control of metabolic acidosis with 5% sodium bicarbonate on early renal function after living donor renal transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1139-1144.
[4]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[5]	WEI Zihan,LI Dongbo，YUAN Zheng,LU Ying, YANG Guojie. Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.
[6]	MENG Jingqian, ZHAO Yingying, ZHANG Wenji, ZHANG Wanzhe, SHEN Pengxiao，LIU Ding, SU Chenhao, SHEN Jie, WANG Jiansheng. Effects of ACE2 polymorphism on the clinical outcomes of irbesartan for the treatment of stage 2 hypertension concomitant with chronic renal failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 661-666.
[7]	YU Li-zhen, BIAN Hui-ming , YU Jing-hua. Effects of Liuweidihuang Formula (LWDHF) on ET,TXA₂,PGI₂ and protecting the endotheliocytes in the blood plasma of rats with hyperlipidemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 503-506.
[8]	LI Pei-wu, WANG Xian-kun, CHONG Xiao-qin, LI Pei-jie, CUI Hong-bin, LU Yan, FU Zhong-xue. Cardiovascular responses evoked by endothelin-1(1-31) microinjected into the nucleus tractus solitarius [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 754-759.
[9]	HUANG Yuan-yuan, ZHANG Hao, YI bing, FU Zhi-min, YANG Guo-ping. Advances of the influence of chronic renal failure on the pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 715-720.
[10]	CHEN Ai-dong, LI Juan, XIE Hai-tang. Recent research progress in cardiovascular effects of endothelin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(8): 937-944.
[11]	LI Ling, TAN Zhi-rong, CHEN Yao, ZHOU Gan, GUO Dong, YAN Jin, YANG Guo-ping, OUYANG Dong-sheng. A rapid and sensitive LC-MS/MS method for determination of valsartan in human plasma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 809-813.
[12]	FAN Xiao, XU Yang, ZHANG Hong-liang. Protective effects of Omeprazole on the toxic acute gastric mucosal lesion in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(6): 626-630.
[13]	WU Xiao-dong, ZHANG Dao-you, CUI Ming-chun, YANG Li-cai, YANG Yan-lang, ZHU Xin-jian. Influence of valsartan and fluvastatin on hepatocyte growth factor in adriamycin-induced nephrotic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 305-309.
[14]	SUN Yu-ming, LOU Jian-Tao, HUANG Guang-xiang, SUN Jun. Study on the therapeutic effects of ferulic acid sodium in cerebral hemorrhage model rats induced by collagenase and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1377-1382.
[15]	MAO Yao-sheng, CAO miao-ying, ZHOU Xin. Effects of intensive insulin therapy on the prognosis and serum vWF,ET-1 and NO levels in patients with sepsis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1414-1417.